Akt-inhibitor-resistant derivative BT474 lines were developed by chronically treating tumor cells with gradually increasing doses of inhibitor (starting at 0.2 μM or 1 μM) (Figure 1A). The gene discussed is AKT1; the disease is neoplasm.